All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

53

Reset

53 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • RetatrutideLY3437943Phase 316 trials

    Eli Lilly · Obesity, Overweight, Type 2 Diabetes

  • BrenipatideLY3537031Phase 313 trials

    Eli Lilly · Alcohol Use Disorder, Irritable Bowel Syndrome, Depressive Disorder, Major

  • EloralintideLY3841136Phase 313 trials

    Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2

  • ZanzalintinibXL092Phase 311 trials

    Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • OlomorasibLY3537982Phase 36 trials

    Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis

  • MazdutideLY3305677Phase 35 trials

    Eli Lilly · Type 2 Diabetes, Obesity, Overweight

  • MibavademabREGN4461Phase 35 trials

    Regeneron · Generalized Lipodystrophy, Functional Hypothalamic Amenorrhea, FHA

  • TersolisibLY4064809, STX-478Phase 33 trials

    Eli Lilly · Breast Neoplasms, Neoplasm Metastasis, Breast Cancer

  • TinlarebantLBS-008Phase 33 trials

    Belite Bio, Inc · Stargardt Disease 1, STGD1, Geographic Atrophy

  • AfimetoranBMS-986256, BLN-256Phase 32 trials

    Beeline Medicines Corporation · Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus

  • ClazakizumabLY5724886, CSL300Phase 32 trials

    Eli Lilly · Atherosclerosis, Cardiovascular Disease, Obesity

  • LepodisiranLY3819469Phase 32 trials

    Eli Lilly · Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)

  • VepugratinibLY3866288Phase 32 trials

    Eli Lilly · Urinary Bladder Neoplasms, Urologic Neoplasms, Receptor, Fibroblast Growth Factor, Type 3

  • ATB-1011Phase 31 trial

    Autotelicbio · Essential Hypertension, Diabetes Mellitus, Type 2

  • ATB-1012Phase 31 trial

    Autotelicbio · Essential Hypertension, Diabetes Mellitus, Type 2

  • ATB-1013Phase 31 trial

    Autotelicbio · Essential Hypertension, Diabetes Mellitus, Type 2

  • B2227Phase 31 trial

    Bostal Drug Delivery Co., Ltd · Schizophrenia

  • RemternetugLY3372993Phase 31 trial

    Eli Lilly · Alzheimer's Disease

  • MORF-057zotemtegrast, LY4268989Phase 24 trials

    Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis (UC)

  • antibioticsPhase 23 trials

    TenNor Therapeutics (Zhongshan) Limited · Prosthetic Joint Infection (PJI), Periprosthetic Joint Infection (PJI), Acute Pyelonephritis

  • LY4065967Phase 23 trials

    Eli Lilly · Chronic Pain, Diabetic Peripheral Neuropathic Pain, Osteoarthritis, Knee

  • MacupatideLY3532226Phase 23 trials

    Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2

  • TL-925Phase 23 trials

    Telios Pharma, Inc. · Allergic Conjunctivitis, Allergic Conjunctivitis of Both Eyes

  • BimagrumabLY3985863, BYM338Phase 22 trials

    Eli Lilly · Heart Failure, Diastolic, Diastolic Heart Failure, Heart Failure, Normal Ejection Fraction

  • EltrekibartLY3041658Phase 22 trials

    Eli Lilly · Ulcerative Colitis, Ulcerative Colitis Chronic, Hidradenitis Suppurativa

  • LY188011Phase 22 trials

    Eli Lilly · Neoplasms, Child, Adolescent

  • LY3549492Phase 22 trials

    Eli Lilly · Obesity, Overweight

  • LY4005130Phase 22 trials

    Eli Lilly · Alopecia Areata, Vitiligo, Non-Segmental Vitiligo (NSV)

  • LY4395089Phase 22 trials

    Eli Lilly · Crohn Disease, Colitis, Ulcerative

  • Sutetinib MaleatePhase 22 trials

    Teligene US · Non-small Cell Lung Cancer

  • EI-001Phase 21 trial

    Elixiron Immunotherapeutics (Hong Kong) Ltd. · Non-segmental Vitiligo

  • EI-1071Phase 21 trial

    Elixiron Immunotherapeutics Inc. · Mild, Moderate, or Severe Alzheimer's Disease

  • EL219Phase 21 trial

    Elion Therapeutics, Inc. · Invasive Mould Infection

  • HP-002Phase 21 trial

    Shanghai Helioson Pharmaceutical Co., Ltd. · B-Cell Non-Hodgkin Lymphoma

  • HXN6005Phase 21 trial

    Helixon Biotechnology (Suzhou) Co., Ltd · Health Adult Subjects, Atopic Dermatitis (AD)

  • IVMED-85Phase 21 trial

    iVeena Delivery Systems, Inc. · Myopia, Progressive

  • KELI-101Phase 21 trial

    Kelifarma · Preemptive Therapy of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery

  • LY2784544Phase 21 trial

    Eli Lilly · Neoplasms, Hematologic

  • LY3457263Phase 21 trial

    Eli Lilly · Type 2 Diabetes

  • LY3537021Phase 21 trial

    Eli Lilly · Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions

  • LY3848575Phase 21 trial

    Eli Lilly · Neuropathic Pain, Distal Sensory Polyneuropathy

  • LY3871801Phase 21 trial

    Eli Lilly · Rheumatoid Arthritis

  • LY3938577Phase 21 trial

    Eli Lilly · Diabetes Mellitus, Type 2

  • LY3972406Phase 21 trial

    Eli Lilly · Plaque Psoriasis

  • LY4086940Phase 21 trial

    Eli Lilly · Obesity, Overweight

  • LY4100511Phase 21 trial

    DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · Plaque Psoriasis

  • LY4515100Phase 21 trial

    Eli Lilly · Acute Pain, Molar, Molar, Third

  • MerestinibLY2801653Phase 21 trial

    Eli Lilly · Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer

  • SolbinsiranLY3561774Phase 21 trial

    Eli Lilly · Severe Hypertriglyceridemia

  • TL-895Phase 21 trial

    Telios Pharma, Inc. · Myelofibrosis, Primary Myelofibrosis, Post-PV MF

Page 1 of 2Older

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.